{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,23]],"date-time":"2026-04-23T10:51:35Z","timestamp":1776941495154,"version":"3.51.4"},"reference-count":30,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2014,1,1]],"date-time":"2014-01-01T00:00:00Z","timestamp":1388534400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,1,1]],"date-time":"2014-01-01T00:00:00Z","timestamp":1388534400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"name":"National Science & Technology Major Project \u201cKey New Drug Creation and Manufacturing Program\u201d","award":["2012ZX09301-001"],"award-info":[{"award-number":["2012ZX09301-001"]}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["81021062"],"award-info":[{"award-number":["81021062"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["81173079"],"award-info":[{"award-number":["81173079"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Knowledge Innovation Program of Chinese Academy of Sciences","award":["KSCX2-EW-Q-3"],"award-info":[{"award-number":["KSCX2-EW-Q-3"]}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Letters"],"published-print":{"date-parts":[[2014,1]]},"DOI":"10.1016\/j.canlet.2013.08.046","type":"journal-article","created":{"date-parts":[[2013,9,7]],"date-time":"2013-09-07T09:30:36Z","timestamp":1378546236000},"page":"159-166","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":34,"title":["Systematic combination screening reveals synergism between rapamycin and sunitinib against human lung cancer"],"prefix":"10.1016","volume":"342","author":[{"given":"Xian","family":"Li","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lin-Jiang","family":"Tong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jian","family":"Ding","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ling-Hua","family":"Meng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.canlet.2013.08.046_b0005","doi-asserted-by":"crossref","first-page":"2676","DOI":"10.1158\/1535-7163.MCT-06-0166","article-title":"Rapamycin synergizes with the epidermal growth factor receptor inhibitor erlotinib in non-small-cell lung, pancreatic, colon, and breast tumors","volume":"5","author":"Buck","year":"2006","journal-title":"Molecular Cancer Therapeutics"},{"key":"10.1016\/j.canlet.2013.08.046_b0010","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1038\/nature11252","article-title":"Comprehensive molecular characterization of human colon and rectal cancer","volume":"487","author":"Cancer Genome Atlas","year":"2012","journal-title":"Nature"},{"key":"10.1016\/j.canlet.2013.08.046_b0015","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1016\/j.bcp.2012.01.019","article-title":"Inhibition of tumor cell growth, proliferation and migration by X-387, a novel active-site inhibitor of mTOR","volume":"83","author":"Chen","year":"2012","journal-title":"Biochemical Pharmacology"},{"key":"10.1016\/j.canlet.2013.08.046_b0020","doi-asserted-by":"crossref","first-page":"17414","DOI":"10.1073\/pnas.0809136105","article-title":"Rapamycin differentially inhibits S6Ks and 4E-BP1 to mediate cell-type-specific repression of mRNA translation","volume":"105","author":"Choo","year":"2008","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"10.1016\/j.canlet.2013.08.046_b0025","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1158\/0008-5472.CAN-09-1947","article-title":"Drug combination studies and their synergy quantification using the Chou\u2013Talalay method","volume":"70","author":"Chou","year":"2010","journal-title":"Cancer Research"},{"key":"10.1016\/j.canlet.2013.08.046_b0030","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1038\/nrd2089","article-title":"Strategies for optimizing combinations of molecularly targeted anticancer agents","volume":"5","author":"Dancey","year":"2006","journal-title":"Nature Reviews. Drug Discovery"},{"key":"10.1016\/j.canlet.2013.08.046_b0035","doi-asserted-by":"crossref","unstructured":"L. Ding, G. Getz, D.A. Wheeler, E.R. Mardis, M.D. McLellan, K. Cibulskis, C. Sougnez, H. Greulich, D.M. Muzny, M.B. Morgan, L. Fulton, R.S. Fulton, Q. Zhang, M.C. Wendl, M.S. Lawrence, D.E. Larson, K. Chen, D.J. Dooling, A. Sabo, A.C. Hawes, H. Shen, S.N. Jhangiani, L.R. Lewis, O. Hall, Y. Zhu, T. Mathew, Y. Ren, J. Yao, S.E. Scherer, K. Clerc, G.A. Metcalf, B. Ng, A. Milosavljevic, M.L. Gonzalez-Garay, J.R. Osborne, R. Meyer, X. Shi, Y. Tang, D.C. Koboldt, L. Lin, R. Abbott, T.L. Miner, C. Pohl, G. Fewell, C. Haipek, H. Schmidt, B.H. Dunford-Shore, A. Kraja, S.D. Crosby, C.S. Sawyer, T. Vickery, S. Sander, J. Robinson, W. Winckler, J. Baldwin, L.R. Chirieac, A. Dutt, T. Fennell, M. Hanna, B.E. Johnson, R.C. Onofrio, R.K. Thomas, G. Tonon, B.A. Weir, X. Zhao, L. Ziaugra, M.C. Zody, T. Giordano, M.B. Orringer, J.A. Roth, M.R. Spitz, Wistuba, II, B. Ozenberger, P.J. Good, A.C. Chang, D.G. Beer, M.A. Watson, M. Ladanyi, S. Broderick, A. Yoshizawa, W.D. Travis, W. Pao, M.A. Province, G.M. Weinstock, H.E. Varmus, S.B. Gabriel, E.S. Lander, R.A. Gibbs, M. Meyerson, R.K. Wilson, Somatic mutations affect key pathways in lung adenocarcinoma, Nature 455 (2008) 1069-1075.","DOI":"10.1038\/nature07423"},{"key":"10.1016\/j.canlet.2013.08.046_b0040","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1038\/nrc2664","article-title":"Targeting PI3K signalling in cancer: opportunities, challenges and limitations","volume":"9","author":"Engelman","year":"2009","journal-title":"Nature Reviews. Cancer"},{"key":"10.1016\/j.canlet.2013.08.046_b0045","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1038\/nrd2380","article-title":"Molecular basis for sunitinib efficacy and future clinical development","volume":"6","author":"Faivre","year":"2007","journal-title":"Nature Reviews Drug Discovery"},{"key":"10.1016\/j.canlet.2013.08.046_b0050","doi-asserted-by":"crossref","first-page":"29","DOI":"10.2174\/157489210789702208","article-title":"Inhibitors of the PI3K\/Akt\/mTOR pathway: new hope for breast cancer patients","volume":"5","author":"Ghayad","year":"2010","journal-title":"Recent Patents on Anti-Cancer Drug Discovery"},{"key":"10.1016\/j.canlet.2013.08.046_b0055","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.ccr.2007.05.008","article-title":"Defining the role of mTOR in cancer","volume":"12","author":"Guertin","year":"2007","journal-title":"Cancer Cell"},{"key":"10.1016\/j.canlet.2013.08.046_b0060","doi-asserted-by":"crossref","first-page":"2003","DOI":"10.1016\/j.cellsig.2007.05.013","article-title":"Vascular endothelial growth factor receptor-2: structure, function, intracellular signalling and therapeutic inhibition","volume":"19","author":"Holmes","year":"2007","journal-title":"Cellular Signalling"},{"key":"10.1016\/j.canlet.2013.08.046_b0065","doi-asserted-by":"crossref","first-page":"6882","DOI":"10.1158\/0008-5472.CAN-05-0309","article-title":"RAD001 (everolimus) improves the efficacy of replicating adenoviruses that target colon cancer","volume":"65","author":"Homicsko","year":"2005","journal-title":"Cancer Research"},{"key":"10.1016\/j.canlet.2013.08.046_b0070","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1158\/1535-7163.MCT-09-0952","article-title":"Stage 2 combination testing of rapamycin with cytotoxic agents by the pediatric preclinical testing program","volume":"9","author":"Houghton","year":"2010","journal-title":"Molecular Cancer Therapeutics"},{"key":"10.1016\/j.canlet.2013.08.046_b0075","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1002\/pbc.21296","article-title":"Initial testing (stage 1) of the mTOR inhibitor rapamycin by the pediatric preclinical testing program","volume":"50","author":"Houghton","year":"2008","journal-title":"Pediatric Blood & Cancer"},{"key":"10.1016\/j.canlet.2013.08.046_b0080","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1042\/BST0370217","article-title":"A complex interplay between Akt, TSC2, and the two mTOR complexes","volume":"37","author":"Huang","year":"2009","journal-title":"Biochemical Society Transactions"},{"key":"10.1016\/j.canlet.2013.08.046_b0085","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1056\/NEJMoa066838","article-title":"Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma","volume":"356","author":"Hudes","year":"2007","journal-title":"The New England Journal of Medicine"},{"key":"10.1016\/j.canlet.2013.08.046_b0090","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.jhep.2008.02.022","article-title":"Bevacizumab and rapamycin induce growth suppression in mouse models of hepatocellular carcinoma","volume":"49","author":"Huynh","year":"2008","journal-title":"Journal of Hepatology"},{"key":"10.1016\/j.canlet.2013.08.046_b0095","doi-asserted-by":"crossref","first-page":"2959","DOI":"10.1158\/1535-7163.MCT-07-0237","article-title":"Bevacizumab and rapamycin inhibit tumor growth in peritoneal model of human ovarian cancer","volume":"6","author":"Huynh","year":"2007","journal-title":"Molecular Cancer Therapeutics"},{"key":"10.1016\/j.canlet.2013.08.046_b0100","doi-asserted-by":"crossref","first-page":"R66","DOI":"10.1186\/bcr2903","article-title":"Sunitinib inhibits lymphatic endothelial cell functions and lymph node metastasis in a breast cancer model through inhibition of vascular endothelial growth factor receptor 3","volume":"13","author":"Kodera","year":"2011","journal-title":"Breast Cancer Research"},{"key":"10.1016\/j.canlet.2013.08.046_b0105","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1038\/nrd3216","article-title":"Utilizing targeted cancer therapeutic agents in combination: novel approaches and urgent requirements","volume":"9","author":"Kummar","year":"2010","journal-title":"Nature Reviews. Drug Discovery"},{"key":"10.1016\/j.canlet.2013.08.046_b0110","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.cell.2012.03.017","article-title":"MTOR signaling in growth control and disease","volume":"149","author":"Laplante","year":"2012","journal-title":"Cell"},{"key":"10.1016\/j.canlet.2013.08.046_b0115","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/S0140-6736(08)61039-9","article-title":"Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial","volume":"372","author":"Motzer","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.canlet.2013.08.046_b0120","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1038\/sj.bjc.6605346","article-title":"Phase II study of continuous daily sunitinib dosing in patients with previously treated advanced non-small cell lung cancer","volume":"101","author":"Novello","year":"2009","journal-title":"British Journal of Cancer"},{"key":"10.1016\/j.canlet.2013.08.046_b0125","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1158\/0008-5472.CAN-05-2925","article-title":"MTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt","volume":"66","author":"O\u2019Reilly","year":"2006","journal-title":"Cancer Research"},{"key":"10.1016\/j.canlet.2013.08.046_b0130","doi-asserted-by":"crossref","first-page":"1674","DOI":"10.1093\/annonc\/mdp060","article-title":"Efficacy of everolimus (RAD001) in patients with advanced NSCLC previously treated with chemotherapy alone or with chemotherapy and EGFR inhibitors","volume":"20","author":"Soria","year":"2009","journal-title":"Annals of Oncology: Official Journal of the European Society for Medical Oncology\/ESMO"},{"key":"10.1016\/j.canlet.2013.08.046_b0135","doi-asserted-by":"crossref","first-page":"6993","DOI":"10.1158\/1078-0432.CCR-04-0808","article-title":"Effect of rapamycin alone and in combination with antiangiogenesis therapy in an orthotopic model of human pancreatic cancer","volume":"10","author":"Stephan","year":"2004","journal-title":"Clinical Cancer Research: An Official Journal of the American Association for Cancer Research"},{"key":"10.1016\/j.canlet.2013.08.046_b0140","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1159\/000348584","article-title":"A phase I trial of sunitinib and rapamycin in patients with advanced non-small cell lung cancer","volume":"59","author":"Waqar","year":"2013","journal-title":"Chemotherapy"},{"key":"10.1016\/j.canlet.2013.08.046_b0145","doi-asserted-by":"crossref","first-page":"e20899","DOI":"10.1371\/journal.pone.0020899","article-title":"The combination of RAD001 and NVP-BEZ235 exerts synergistic anticancer activity against non-small cell lung cancer in vitro and in vivo","volume":"6","author":"Xu","year":"2011","journal-title":"PloS One"},{"key":"10.1016\/j.canlet.2013.08.046_b0150","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/j.coph.2008.08.004","article-title":"Targeting the PI3K\u2013AKT\u2013mTOR pathway: progress, pitfalls, and promises","volume":"8","author":"Yap","year":"2008","journal-title":"Current Opinion in Pharmacology"}],"updated-by":[{"DOI":"10.1016\/j.canlet.2019.12.001","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000}}],"container-title":["Cancer Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383513006435?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383513006435?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,4]],"date-time":"2025-10-04T15:34:46Z","timestamp":1759592086000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0304383513006435"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,1]]},"references-count":30,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2014,1]]}},"alternative-id":["S0304383513006435"],"URL":"https:\/\/doi.org\/10.1016\/j.canlet.2013.08.046","relation":{},"ISSN":["0304-3835"],"issn-type":[{"value":"0304-3835","type":"print"}],"subject":[],"published":{"date-parts":[[2014,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Systematic combination screening reveals synergism between rapamycin and sunitinib against human lung cancer","name":"articletitle","label":"Article Title"},{"value":"Cancer Letters","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.canlet.2013.08.046","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 Elsevier Ireland Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}